TWI838114B - 黑皮質素-4受體激動劑在預防或治療罕見遺傳性肥胖中的用途 - Google Patents

黑皮質素-4受體激動劑在預防或治療罕見遺傳性肥胖中的用途 Download PDF

Info

Publication number
TWI838114B
TWI838114B TW112104117A TW112104117A TWI838114B TW I838114 B TWI838114 B TW I838114B TW 112104117 A TW112104117 A TW 112104117A TW 112104117 A TW112104117 A TW 112104117A TW I838114 B TWI838114 B TW I838114B
Authority
TW
Taiwan
Prior art keywords
acid
compound
pyrrolidine
pomc
pharmaceutically acceptable
Prior art date
Application number
TW112104117A
Other languages
English (en)
Chinese (zh)
Other versions
TW202339761A (zh
Inventor
朴熙東
黃蕙敬
余秀眞
Original Assignee
南韓商Lg化學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南韓商Lg化學股份有限公司 filed Critical 南韓商Lg化學股份有限公司
Publication of TW202339761A publication Critical patent/TW202339761A/zh
Application granted granted Critical
Publication of TWI838114B publication Critical patent/TWI838114B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW112104117A 2022-02-08 2023-02-06 黑皮質素-4受體激動劑在預防或治療罕見遺傳性肥胖中的用途 TWI838114B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20220016377 2022-02-08
KR10-2022-0016377 2022-02-08

Publications (2)

Publication Number Publication Date
TW202339761A TW202339761A (zh) 2023-10-16
TWI838114B true TWI838114B (zh) 2024-04-01

Family

ID=87564659

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112104117A TWI838114B (zh) 2022-02-08 2023-02-06 黑皮質素-4受體激動劑在預防或治療罕見遺傳性肥胖中的用途

Country Status (13)

Country Link
US (1) US20250134898A1 (cg-RX-API-DMAC7.html)
EP (1) EP4461297A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025505229A (cg-RX-API-DMAC7.html)
KR (1) KR20230120106A (cg-RX-API-DMAC7.html)
CN (1) CN119300835A (cg-RX-API-DMAC7.html)
AR (1) AR128463A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023218785A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248118A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002389A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024011882A2 (cg-RX-API-DMAC7.html)
MX (1) MX2024009854A (cg-RX-API-DMAC7.html)
TW (1) TWI838114B (cg-RX-API-DMAC7.html)
WO (1) WO2023153762A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3202315A1 (en) * 2020-12-22 2022-06-30 Hee Dong Park Use as selective agonist of malanocortin-4 receptor
KR20250046623A (ko) * 2023-09-27 2025-04-03 주식회사 엘지화학 멜라노코르틴-4 수용체 효능제의 pcsk1 결핍 적응증과 연관된 희귀성 유전적 비만질환의 예방 또는 치료 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813032A (en) * 2006-07-14 2008-03-16 Lg Life Sciences Ltd Melanocortin receptor agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12516047B2 (en) * 2019-11-07 2026-01-06 Lg Chem, Ltd. Melanocortin-4 receptor agonists
CN116507615A (zh) * 2020-10-29 2023-07-28 株式会社Lg化学 黑皮质素受体激动剂化合物的晶型i及其制备方法
TWI804170B (zh) * 2021-01-21 2023-06-01 南韓商Lg化學股份有限公司 黑皮質素-4受體促效劑的用途
TWI826938B (zh) * 2021-02-26 2023-12-21 南韓商Lg化學股份有限公司 黑皮質素-4受體促效劑
TWI861780B (zh) * 2022-03-28 2024-11-11 南韓商Lg化學股份有限公司 預防或治療肥胖的聯合療法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813032A (en) * 2006-07-14 2008-03-16 Lg Life Sciences Ltd Melanocortin receptor agonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 Peter Kühnen, M.D., et al., Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist, N Engl J Med, 375:240-246, 2016/07/21 *
期刊 Peter Kühnen, M.D., et al., Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist, N Engl J Med, 375:240-246, 2016/07/21。

Also Published As

Publication number Publication date
JP2025505229A (ja) 2025-02-21
AU2023218785A1 (en) 2024-08-22
CA3248118A1 (en) 2025-01-24
WO2023153762A1 (ko) 2023-08-17
EP4461297A4 (en) 2025-04-09
CL2024002389A1 (es) 2025-01-31
TW202339761A (zh) 2023-10-16
CN119300835A (zh) 2025-01-10
AR128463A1 (es) 2024-05-08
CO2024011882A2 (es) 2025-01-23
EP4461297A1 (en) 2024-11-13
US20250134898A1 (en) 2025-05-01
KR20230120106A (ko) 2023-08-16
MX2024009854A (es) 2024-11-08

Similar Documents

Publication Publication Date Title
TWI861780B (zh) 預防或治療肥胖的聯合療法
TWI804170B (zh) 黑皮質素-4受體促效劑的用途
EP4461297A1 (en) Use of melanocortin-4 receptor agonist in preventing or treating rare genetic obesity disease
EP4299572A1 (en) Melanocortin-4 receptor agonist
EP4265255A1 (en) Use as selective agonist of malanocortin-4 receptor
CN117242064A (zh) 黑皮质素受体激动剂化合物的晶型v及其制备方法
RU2850792C1 (ru) Применение агониста рецептора меланокортина-4
HK40119184A (en) Use of melanocortin-4 receptor agonist in preventing or treating rare genetic obesity disease
KR20250108398A (ko) Lepr 이형접합 결핍 희귀성 유전적 비만 질환의 예방, 개선 또는 치료에서의 멜라노코르틴-4 수용체 효능제의 용도
KR20250100260A (ko) Sh2b1 결핍 희귀성 유전적 비만 질환의 예방, 개선 또는 치료에서의 멜라노코르틴-4 수용체 효능제의 용도
AU2024351762A1 (en) Use of melanocortin-4 receptor agonists for the treatment of pcsk1 deficiency indications
WO2025144899A1 (en) Use of melanocortin-4 receptor agonists for the treatment of a lepr and/or sh2b1 deficiency